Financial Performance - The company's operating revenue for the first half of 2023 was CNY 167.21 million, an increase of 2.11% compared to CNY 163.76 million in the same period last year[17]. - The net profit attributable to shareholders was CNY 12.99 million, representing a growth of 26.28% from CNY 10.29 million year-on-year[17]. - The net profit after deducting non-recurring gains and losses was CNY 12.28 million, up 23.81% from CNY 9.92 million in the previous year[17]. - The basic earnings per share increased to CNY 0.0344, a rise of 25.55% from CNY 0.0274 in the previous year[18]. - The diluted earnings per share also rose to CNY 0.0343, reflecting a 26.57% increase from CNY 0.0271 year-on-year[18]. - The weighted average return on equity improved to 1.93%, an increase of 0.43 percentage points compared to 1.50% in the previous year[18]. - The total operating revenue for the first half of 2023 was CNY 167 million, representing a year-on-year increase of 2.11% from CNY 164 million[42]. - The net profit attributable to shareholders for the same period was CNY 12.9996 million, with a net profit excluding non-recurring items of CNY 12.2771 million[42]. - The company reported a net profit distribution of CNY 1,887,207.90 for the current period, which is part of the profit allocation strategy[126]. Cash Flow and Investments - The company's cash flow from operating activities was CNY 6.15 million, a decrease of 37.23% compared to CNY 9.79 million in the same period last year[17]. - The net cash flow from operating activities fell by 37.23% to CNY 6,145,234.85, mainly due to a reduction in tax refunds received compared to the previous year[47]. - The company reported a net cash outflow from investment activities of CNY 76,785,978.98, a 107.54% increase from the previous year's outflow of CNY 36,997,921.00, primarily due to increased investments in bank wealth management products[47]. - Cash outflow from investment activities significantly increased to CNY 101,792,493.25 in the first half of 2023, compared to CNY 50,277,640.09 in the same period of 2022, marking an increase of 102.36%[116]. - The net cash flow from investment activities was negative CNY 76,785,978.98 for the first half of 2023, worsening from negative CNY 36,997,921.00 in the first half of 2022[116]. Market and Industry Outlook - The CRO industry in China is projected to reach a market size of $22.2 billion by 2024, with a compound annual growth rate (CAGR) of 26.5%[24]. - The global CRO industry is expected to reach $96 billion by 2024, with a CAGR of 10.3%[24]. - The company is positioned to capitalize on the growing demand for pharmaceutical services driven by an aging population and increasing health needs in China[24]. Operational Highlights - The company signed new orders worth CNY 250 million during the reporting period, with a growth rate of 17.07%[19]. - The company provides a comprehensive range of services, including drug discovery, clinical trials, and regulatory submissions, enhancing operational efficiency and revenue generation[26]. - The company emphasizes a one-stop service advantage in drug development, which improves success rates and reduces costs for clients[35]. - The company’s clinical research services include I-IV phase trials and bioequivalence studies, ensuring comprehensive support for drug efficacy and safety[29]. - The company has developed over 350 new drug technologies and obtained more than 400 production and clinical approval documents in China[37]. Employee and Corporate Governance - The company has a workforce of 757 employees, with 86% holding a bachelor's degree or higher, including 119 with master's or doctoral degrees[41]. - The company has undergone changes in its board of directors, with Tao Jing resigning and Cai Ziyun being elected as a new director[70]. - Tao Jing resigned as a director and vice president of the company on March 3, 2023, and the board approved the appointment of Cai Ziyun as a new director on May 10, 2023[71]. Environmental and Compliance - The company has not faced any environmental violations or penalties during the reporting period, adhering strictly to environmental management regulations[77]. - The company has implemented various environmental management systems and conducted regular inspections to ensure compliance with pollution control standards[78]. - The company promotes low-carbon practices among employees, advocating for energy-saving measures and resource conservation[79]. Related Party Transactions and Commitments - The company confirmed that it will not engage in any business activities that compete with its listed company's existing or future operations, ensuring no conflicts of interest[82]. - The commitment includes a promise to minimize or avoid related party transactions, adhering to market rules and fair principles[82]. - The company has pledged to disclose any related party transactions in a timely manner, ensuring transparency and compliance with legal regulations[82]. Shareholder Information - The total number of shares increased from 377,671,585 to 378,223,455 due to the exercise of stock options, representing an increase of 0.03%[95]. - The total number of shareholders reached 14,869 by the end of the reporting period[97]. - The stock option plan has resulted in a total of 1,060,000 stock options held by directors and executives, with 97,500 shares exercised during the reporting period[102]. Financial Reporting and Accounting Policies - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations for the next 12 months[143]. - The company adheres to the Chinese Accounting Standards, ensuring that its financial reports accurately reflect its financial position and operating results[145]. - The company recognizes minority interests and losses separately in the consolidated financial statements, ensuring accurate representation of net profit attributable to minority shareholders[156].

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2023-052 新疆百花村医药集团股份有限公司 关于对 2021 年股票期权激励计划股票期权 部分注销完成的公告 特此公告。 新疆百花村医药集团股份有限公司董事会 2023 年 8 月 23 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 新疆百花村医药集团股份有限公司（以下简称"公司"）于 2023 年 7 月 31 日召开了第八届董事会第十七次会议、第八届监事会第十三次会议，审议通过了 《新疆百花村医药集团股份有限公司关于对 2021 年股票期权激励计划股票期权 部分予以注销的公告》。 根据《上市公司股权激励管理办法》《公司 2021 年股票期权激励计划（草 案）》相关规定，公司对 2021 年股票期权激励计划首次授予和预留授予激励对 象未达到行权条件、经考核行权系数确定为 B 级、C 级、D 级的员工部分股票期 权，合计 1,586,825 份股票期权进行注销，注销工作完成后，公司 2021 年股票期 权激励计划首次授予和预 ...

关于新疆百花村医药集团股份有限公司 向特定对象发行股票的审核中心意见落实函 之回复报告 保荐机构（主承销商） 平安证券股份有限公司 （深圳市福田区福田街道益田路 5023 号平安金融中心 B 座第 22-25 层） 7-1-1 上海证券交易所： 贵所于 2023 年 7 月 1 日出具的上证上审（再融资）〔2023〕446 号《关于新 疆百花村医药集团股份有限公司向特定对象发行股票的审核意见落实函》（以下 简称"意见落实函"）已收悉，平安证券股份有限公司作为保荐机构（主承销 商）（以下简称"保荐机构"），与新疆百花村医药集团股份有限公司（以下简 称"发行人"、"公司"）及希格玛会计师事务所（特殊普通合伙）（以下简称 "发行人会计师"）对意见落实函所列问题认真进行了逐项落实，现回复如下， 请予审核。 保荐机构对本回复材料中的发行人回复进行了逐项核查，确认并保证其真 实、完整、准确。 如无特别说明，本回复报告中的简称或名词的释义与《新疆百花村医药集团 股份有限公司 2021 年度向特定对象发行 A 股股票募集说明书》（以下简称"募 集说明书"）中的相同。 本回复报告的字体代表以下含义： 第 1 题 1、请发行人： ...

新疆百花村医药集团股份有限公司 公司收到《落实函》后，按照要求会同相关中介机构就《落实函》提出的问 题进行了逐项落实，现对相关回复进行公开披露。具体内容详见公司同日在上交 所网站（http://www.sse.com.cn）披露的《关于新疆百花村医药集团股份有限公 司向特定对象发行股票的审核中心意见落实函之回复报告》及其他相关文件。公 司将于回复披露后按要求向上交所报送回复材料。 公司本次向特定对象发行股票相关事项尚需通过上交所审核，并获得中国证 券监督管理委员会（以下简称"中国证监会"）做出同意注册的决定后方可实施， 最终能否通过上交所审核，并获得中国证监会同意注册的决定及时间尚存在不确 定性。公司将根据该事项的进展情况及时履行信息披露义务。敬请广大投资者注 意投资风险。 特此公告。 证券代码：600721 证券简称：百花医药 公告编号：2023-051 新疆百花村医药集团股份有限公司 关于向特定对象发行股票审核中心意见落实函回复报告的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 新疆百花村医药集团股份 ...

希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司向特定对象发行股票的审 核中心意见落实函之回复报告 上海证券交易所: 贵所于 2023年7月1日出具的上证上审(再融资)(2023)446 号《关于新疆 百花村医药集团股份有限公司向特定对象发行股票的审核意见落实函》(以下简称 "意见落实函")已收悉。根据贵所问询函提出的要求,我们在审慎核查的基础上, 就问询两中的有关问题回复说明如下: 请发行人:(1)结合公司各业务板块开展情况、成本费用变化等,具体分析 2022 年度公司亏损的原因,相关影响因素是否将对公司经营业绩造成持续影响; (2) 补充说明 2022 年度公司存货计提大额减值的具体依据及合理性,并说明其 他合同订单是否存在类似需要计提减值的情况;(3)结合上述情况进一步说明公 司主营业务前景,相关业务经营是否稳定。 请保荐机构及申报会计师进行核查并发表明确意见。 【回复】 一、请发行人说明 (一)结合公司各业务板块开展情况、成本费用变化等,具体分析 2022 年度 公司亏损的原因,相关影响因素是否将对 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2023-041 新疆百花村医药集团股份有限公司 关于参加新疆辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，新疆百花村医药集团股份有限公司（以 下简称"公司"）将参加由新疆证监局、新疆上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年新疆辖区上市公司投资者集体接待日活动"，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 6 月 16 日（周五）15:30-18:00。届时公司 高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告。 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2023-032 新疆百花村医药集团股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 16 日(星期二) 下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频播放和网络互动 投资者可于 2023 年 05 月 09 日(星期二) 至 05 月 15 日(星期一)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏 目或通过公司邮箱 bhc@xjbhc.org 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 新疆百花村医药集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 12 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 75,710,434.22, representing an increase of 28.77% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was CNY 6,686,853.20, a significant increase of 387.32% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 6,225,735.69, reflecting a remarkable increase of 558.28% compared to the previous year[5] - The basic earnings per share for Q1 2023 was CNY 0.0177, up by 378.38% year-on-year[5] - The total revenue for Q1 2023 was ¥75,710,434.22, representing an increase of 28.7% compared to ¥58,796,482.88 in Q1 2022[18] - The net profit for Q1 2023 was ¥6,686,853.20, a significant increase from ¥1,378,890.58 in Q1 2022, marking a growth of 385.5%[19] - The basic earnings per share of ¥0.0177 for Q1 2023, compared to ¥0.0037 in Q1 2022, representing a growth of 378.4%[19] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 1,005,621,806.46, a slight increase of 0.43% from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to ¥1,005,621,806.46, slightly up from ¥1,001,329,612.78 as of December 31, 2022[15] - The total liabilities decreased to ¥328,960,581.90 from ¥334,306,129.32, indicating a reduction of approximately 1.0%[16] - The equity attributable to shareholders increased to CNY 676,661,224.56, marking a growth of 1.44% compared to the end of the previous year[6] Cash Flow - The company reported a net cash flow from operating activities of CNY -11,349,578.00, indicating a decrease of 10.51% year-on-year[5] - In Q1 2023, the cash inflow from operating activities was CNY 66,346,463.62, an increase of 12.5% compared to CNY 59,101,524.63 in Q1 2022[21] - The net cash flow from operating activities was -CNY 11,349,578.00, showing an improvement from -CNY 12,682,485.50 in the same period last year[21] - The total cash and cash equivalents at the end of Q1 2023 were CNY 70,793,279.18, compared to CNY 49,289,567.66 at the end of Q1 2022, reflecting a year-over-year increase of 43.7%[22] - The company reported a total cash outflow from operating activities of CNY 77,696,041.62, up from CNY 71,784,010.13 in Q1 2022, indicating a 8.5% increase[21] Research and Development - Research and development expenses increased by 41.02% year-on-year, primarily due to increased investment in pharmaceutical research[9] - Research and development expenses for Q1 2023 were ¥6,139,950.63, up from ¥4,354,071.54 in Q1 2022, an increase of 40.9%[18] Investment Income - The company experienced a 170.93% increase in investment income, attributed to profits from its associate company[9] - The company received CNY 192,022.02 in investment income, up from CNY 97,648.93 in Q1 2022, marking a 96.5% increase[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,280[10]

1、根据申请人《二次反馈意见回复》,2020年根据中国国际贸易仲裁委员 会于 2020 年 4 月 13 日就发行人与张孝清关于《盈利预测补偿协议》仲裁出具 的《裁决书》(〔2020〕中国贸仲京裁字第 0496 号)之裁定结果,申请人对 2018 年财务数据进行会计差错更正,确认业绩补偿金额调整了 2018年营业外收入增 加 13,257.32 万元。2020年申请人一次性大规模终止 79 项合同,导致当年冲减 收入 11,463.58 万元,并补转成本 1,689.64 万元。华威医药相当一部分在研项目 未预期完成且这些项目开始时间久远(有的甚至超过10年),截止 2021年底上 述合同资产余额 15,317.85 万元,已计提坏账准备 2,922.64 万元。礼华生物存在 同样的问题。 请申请人:(1)说明将上述事项确定为会计差错并进行追溯调整是否符合 会计准则的相关规定;(2)说明 2020 年一次性大规模终止合同导致当年大额收 入冲减的原因,相关情况在之前年度是否已经存在,上述合同对应的存货于 2019 年底是否存在重大减值迹象;(3)结合期后结算情况,说明相关合同资产减值 准备计提的合理性和充分性; ...

请发行人说明:(1) 公司一致性评价业务 2019年采用完工百分比法确认收入 的原因,与采用形象进度法确认收入的差异、对经营业绩的具体影响;(2)公司 各项业务设置不同收入确认时点和确认比例的原因及合理性,与行业可比公司是 否一致,各时点收入比例确认的依据,按行业通行的确认时点和确认比例模拟测 算公司收入、成本及利润情况,是否存在显著差异;(3)2020年后,相关节点收 入确认比例显著提高的原因、依据及合理性,是否符合业务开展实际,对经营业 绩的具体影响,是否存在通过变更会计政策调节业绩的情况。 希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司向特定对象发行股票 申请文件的审核问询顾回复 上海证券交易所: 贵所于 2023年3月23日出具的上证上审(再融资)(2023)146号《关于新 疆百花村医药集团股份有限公司向特定对象发行股票申请文件的审核问询函》(以 下简称"问询函")已收悉。根据贵所问询函提出的要求,我们在审慎核查的基础 上,就问询函中的有关问题回复说明如下: 1、根据申报材料,发行人主要以形象进 ...